{"id":17465,"date":"2020-06-24T14:29:00","date_gmt":"2020-06-24T12:29:00","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=17465"},"modified":"2020-06-30T14:31:36","modified_gmt":"2020-06-30T12:31:36","slug":"biogeneration-ventures-closes-bgv-iv-fund-at-e105-million","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\/","title":{"rendered":"BioGeneration Ventures closes BGV IV fund at \u20ac105 million"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">BioGeneration Ventures\u00a0(BGV), a leading early-stage VC in European biopharma, announces the closing of its fourth fund, BGV IV, at \u20ac105 million ($119 million). Strong market interest expediated the fund raise, with the commitments to date exceeding the fund\u2019s original target.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The BGV IV fund has attracted notable institutions as investors such as, Bristol Myers Squibb, Schroder Adveq and the European Investment Fund. New investors to BGV IV include Industriens Pension and KfW Capital.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">BGV is one of the largest VC funds in Europe focused on early investments in new bio-technology companies, with over \u20ac 220 million assets under management. Its team has broad experience in investment, life sciences, business development, and commercial operations. It also draws on experienced biotech entrepreneurs as venture partners and advisors, to the benefit of its portfolio companies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Company\u2019s approach is to partner with scientists from major European institutions and entrepreneurs. The aim is to build new companies, around either single assets or technology platforms with the goal of creating transformational new medicines. This strategy is supported by the strong collaboration between BGV and Forbion, providing a platform across early- to late-stage companies.&nbsp;&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The investment strategy for the BGV IV fund will follow the same successful path as BGV\u2019s other funds, which have resulted in innovative new medicines reaching patients and yielded significant returns for investors.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Portfolio successes of earlier BGV funds include Acerta Pharma, which was acquired by AstraZeneca for up to $7bn and&nbsp;<a href=\"https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/calquence-approved-in-the-us-for-adult-patients-with-chronic-lymphocytic-leukaemia-21112019.html\">whose lead product Calquence\u00ae is now approved and marketed in the US<\/a>,&nbsp;and Staten Biotechnology, which signed a \u20ac430 million exclusive option deal with Novo Nordisk.&nbsp; Other companies in the current BGV portfolio include NorthSea Therapeutics, Azafaros, Varmx, and Confo Therapeutics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Edward van Wezel, BGV\u2019s Managing Partner&nbsp;said:<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>\u201c<\/em><em>Over the last few years, BGV has demonstrated that investing in early-stage companies in Europe can bring innovative science to meet patients\u2019 needs worldwide as well as financial value to investors. With this new fund, we are pleased to have the backing of some of our long-standing investors; we also welcome our new investors, Industriens Pension and KfW Capital.&nbsp; The early-stage science coming out of European Institutions is second to none and we are working with those at the forefront of their fields. We believe we can make a significant difference to companies in helping them translate promising science into transformational new medicines.\u201d<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Frederik Fischer Hjerl, Investment Manager at Industriens Pension, added:<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>\u201cAs a new investor to the BGV fund, we have had a lot of focus at the BGV team\u2019s strong track record and their approach towards early innovation. There is an urgent demand for new medicines which might accelerate the level of innovation coming out of research institutions across Europe. Having an experienced team like BGV, which in multiple occasions has proven capable of identifying and nurturing the potential future stars, is crucial to bringing new ideas forward. We look forward to working with BGV to help bring new medicines through.\u201d<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Source: <a href=\"https:\/\/www.biogenerationventures.com\/news-releases\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\/\"><strong>BGV (press release)<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BioGeneration Ventures\u00a0(BGV), a leading early-stage VC in European biopharma, announces the closing of its fourth fund, BGV IV, at \u20ac105 million ($119 million). Strong market interest expediated the fund raise, with the commitments to date exceeding the fund\u2019s original target. The BGV IV fund has attracted notable institutions as investors such as, Bristol Myers Squibb, [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[43],"tags":[],"class_list":["post-17465","post","type-post","status-publish","format-standard","hentry","category-innovatieklimaat"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioGeneration Ventures closes BGV IV fund at \u20ac105 million - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioGeneration Ventures closes BGV IV fund at \u20ac105 million - hollandbio\" \/>\n<meta property=\"og:description\" content=\"BioGeneration Ventures\u00a0(BGV), a leading early-stage VC in European biopharma, announces the closing of its fourth fund, BGV IV, at \u20ac105 million ($119 million). Strong market interest expediated the fund raise, with the commitments to date exceeding the fund\u2019s original target. The BGV IV fund has attracted notable institutions as investors such as, Bristol Myers Squibb, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-24T12:29:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-06-30T12:31:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"hollandbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hollandbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\\\/\"},\"author\":{\"name\":\"hollandbio\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\"},\"headline\":\"BioGeneration Ventures closes BGV IV fund at \u20ac105 million\",\"datePublished\":\"2020-06-24T12:29:00+00:00\",\"dateModified\":\"2020-06-30T12:31:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\\\/\"},\"wordCount\":512,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Innovatieklimaat\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\\\/\",\"name\":\"BioGeneration Ventures closes BGV IV fund at \u20ac105 million - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2020-06-24T12:29:00+00:00\",\"dateModified\":\"2020-06-30T12:31:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioGeneration Ventures closes BGV IV fund at \u20ac105 million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\",\"name\":\"hollandbio\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioGeneration Ventures closes BGV IV fund at \u20ac105 million - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\/","og_locale":"en_US","og_type":"article","og_title":"BioGeneration Ventures closes BGV IV fund at \u20ac105 million - hollandbio","og_description":"BioGeneration Ventures\u00a0(BGV), a leading early-stage VC in European biopharma, announces the closing of its fourth fund, BGV IV, at \u20ac105 million ($119 million). Strong market interest expediated the fund raise, with the commitments to date exceeding the fund\u2019s original target. The BGV IV fund has attracted notable institutions as investors such as, Bristol Myers Squibb, [&hellip;]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\/","og_site_name":"hollandbio","article_published_time":"2020-06-24T12:29:00+00:00","article_modified_time":"2020-06-30T12:31:36+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"hollandbio","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"hollandbio","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\/"},"author":{"name":"hollandbio","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb"},"headline":"BioGeneration Ventures closes BGV IV fund at \u20ac105 million","datePublished":"2020-06-24T12:29:00+00:00","dateModified":"2020-06-30T12:31:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\/"},"wordCount":512,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Innovatieklimaat"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\/","name":"BioGeneration Ventures closes BGV IV fund at \u20ac105 million - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2020-06-24T12:29:00+00:00","dateModified":"2020-06-30T12:31:36+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"BioGeneration Ventures closes BGV IV fund at \u20ac105 million"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb","name":"hollandbio"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/17465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=17465"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/17465\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=17465"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=17465"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=17465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}